Compound News and Research

RSS

A single dose of a test vaccine sprayed into the nose protects monkeys against the SARS virus

The study, published in the June 26 issue of the British journal The Lancet, is the third recently issued by NIAID that describes a promising candidate vaccine against SARS.

25 Jun 2004

Ingredient of human breast milk may be a new treatment for warts

New Swedish research suggests that HAMLET or "Human-lactalbumin made lethal to tumor cells" an ingredient of human breast milk may be a new treatment for warts.

24 Jun 2004

Results give Washington dairy cattle all clear from toxic substances

The Food and Drug Administration's Forensic Chemical Center (FCC) laboratory in Cincinnati has completed its testing of milk samples from cows exposed to a toxic substance in Washington State.

24 Jun 2004

We want to figure out how to grow new kidneys in humans

Growing new organs to take the place of damaged or diseased ones is moving from science fiction to reality, according to researchers at Washington University School of Medicine in St. Louis.

22 Jun 2004

Food labels will have to list certain ingredients that people may be allergic to (allergens)

The UK Food Standards Agency has launched a public consultation on new food labelling rules that will mean food labels will have to list certain ingredients that people may be allergic to (allergens).

21 Jun 2004

Paclitaxel analog kills more cancer cells than natural product

Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.

21 Jun 2004

Drug for multiple sclerosis prevented disease development when tested on animal models

Scientists from the Neurological Sciences Institute at Oregon Health & Science University have shown that an investigative drug for multiple sclerosis and related diseases prevented disease development when tested on animal models.

20 Jun 2004

Significant vaccine advance for Parkinson’s disease therapy

Scientists at the University of Nebraska Medical Center in Omaha and Columbia University Medical Center in New York have discovered a new vaccine approach that successfully prevents the death of brain cells in a mouse model of Parkinson’s disease.

15 Jun 2004

Project aimed at eliminating anthrax as a potential weapon for terrorists

La Trobe University scientists are using their own unique peptide 'library' containing a thousand million molecular sequences in a project aimed at eliminating anthrax as a potential weapon for terrorists.

10 Jun 2004

FDA warns against use of domperidone to increase milk production

In response to reports that women may be using an unapproved drug, domperidone, to increase milk production (lactation), the Food and Drug Administration (FDA) is warning breastfeeding women not to use this product because of safety concerns. Today, FDA also issued six letters to pharmacies that compound products containing domperidone and firms that supply domperidone for use in compounding.

9 Jun 2004

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).

9 Jun 2004

Researchers win Kaye prize for gastro-retentive sustained release drug delivery system

Despite advances made in "sustained delivery" drug delivery technologies in recent years, a problem still persists in trying to obtain controlled release of a wide variety of medications that have only a "narrow absorption window" in the upper part of the intestines. That is, these drugs are absorbed rather quickly after being swallowed, negating the beneficial effects of "once-a-day" medication.

9 Jun 2004

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.

7 Jun 2004